| Bioactivity | GW 610 (NSC 721648), an antitumor agent, shows potent and selective anticancer activity against lung, colon, and breast cancer cell lines[1][2][3]. |
| Invitro | GW 610 inhibits the proliferation of MCF-7, MDA 468, KM 12, and HCC 2998 cells, with GI50s of <0.1 nM, <0.1 nM, 290 nM, and 0.25 nM, respectively[1].GW 610 (0.1-1 μM) induces CYP1A1 mRNA and protein in MDA-MB-468, MCF-7, KM12, and HCC2998 cells, whereas CYP2S1 and CYP2W1 are induced only in breast cancer cells[3]. Western Blot Analysis[3] Cell Line: |
| Name | GW 610 |
| CAS | 872726-44-8 |
| Formula | C15H12FNO2S |
| Molar Mass | 289.32 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |
| Reference | [1]. Mortimer CG, et, al. Antitumor benzothiazoles. 26.(1) 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW 610, NSC 721648), a simple fluorinated 2-arylbenzothiazole, shows potent and selective inhibitory activity against lung, colon, and breast cancer cell [2]. Aiello S, et, al. Synthesis and biological properties of benzothiazole, benzoxazole, and chromen-4-one analogues of the potent antitumor agent 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (PMX 610, NSC 721648). J Med Chem. 2008 Aug 28;51(16):5135-9. [3]. Tan BS, et, al. CYP2S1 and CYP2W1 mediate 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW-610, NSC 721648) sensitivity in breast and colorectal cancer cells. Mol Cancer Ther. 2011 Oct;10(10):1982-92. |